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Abstract: The growth hormone/insulin-like growth factor I (GH/IGF-I) axis is an important regulator of brain function 
which view is based on the evidence that 1) GH and IGF-I can cross the blood brain barrier, 2) GH and IGF-I can bind to 
sites in various brain structures, including the hippocampus, 3) GH can alter the dopamine turnover in the hippocampus 
and IGF-I the acetylcholine release, and 4) GH and IGF-I can activate the NMDA receptor in the hippocampus. These 
mechanisms may underlie the relationship between the GH/IGF-I axis and cognitive functioning. A reduced activity of the 
GH/IGF-I axis seems associated with cognitive dysfunction in adult patients with GH deficiency (GHD), Prader-Willi 
syndrome, traumatic brain injury (TBI), dementia and also with age-associated cognitive decline in healthy elderly. 
Moreover, IGF-I deficiency may be involved in the aetiology of schizophrenia. Treatment with GH appears to have a 
beneficial effect on cognitive functions in patients with GHD, Prader-Willi and TBI. However, as evidence of GH 
replacement on cognition in distinct groups is limited and diet, exercise, and specific medicines have known effects on the 
GH/IGF-I axis, future studies on the relationship between GH-, diet-, exercise-, or medication-induced GH/IGF-I increase 
and cognition are required. 
Keywords: Growth hormone, insulin-like growth factor I, cognition, Prader Willi syndrome, traumatic brain injury, dementia, 
schizophrenia, leukemia. 
THE GH/IGF-I AXIS AND BRAIN FUNCTION 
 Apart from regulating somatic growth and metabolism, it 
is generally acknowledged that the growth hormone/insulin-
like growth factor I (GH/ IGF-I) axis plays an important role 
in the regulation of brain function. Currently, there is 
substantial evidence that GH as well as IGF-I can affect 
cognition and biochemical processes in the adult brain. Some 
cognitive effects of GH may result from the direct action of 
GH on the central nervous system (CNS), while other effects 
may be mediated by circulating IGF-I or be due to locally 
produced IGF-I within the brain [1]. More than a decade ago 
it was demonstrated in GH deficient patients that GH could 
pass from the circulation into the CSF [2] and another 
decade after this finding GH injected in mice and rats was 
found to cross the blood brain barrier (BBB) of these animals 
[3]. As in the last study no specific transport system for GH 
could be demonstrated, the brain influx of GH was 
concluded to be established by simple diffusion. Similar to 
GH, radiolabeled IGF-I injected in mice has been found to 
cross the blood brain barrier. However, with respect to IGF-I 
the passage is likely established by a saturable high capacity 
transport system instead of simple diffusion [4]. 
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 There are binding sites for GH in brain structures such as 
the choroid plexus, hypothalamus and hippocampus. GH 
receptors located in the choroid plexus have been suggested 
to play a role in the receptor-mediated transport of GH 
across the BBB and GH receptors in the hypothalamus are 
likely involved in the regulatory mechanism for hormone 
secretion. The functions mediated by the GH receptors 
identified in the hippocampus may be involved in the 
hormone's action on memory and cognitive functions [5]. 
Moreover, GH treatment changes the concentration of CSF 
levels of the dopamine (DA) metabolite homovanillic acid 
(HVA) and the excitatory amino acid aspartate, a ligand for 
the N-methyl-D-aspartate (NMDA) receptor [2,6,7]. 
Alteration of the DA turnover in the dopamine-rich 
hippocampus may influence memory functions and 
activation of the NMDA receptor may contribute to long-
term potentiation of synaptic efficacy in the hippocampus, 
leading to memory consolidation [8]. Indeed, le Grevès et al. 
[9] showed that GH administration in rats increases the 
expression of hippocampal mRNA for the NMDA subunit 
2B. This finding indicates that GH may directly and 
indirectly (via aspartate) affect the hippocampal NMDA 
receptor. 
 Also for IGF-I there are specific binding sites in the brain 
such as in the choroid plexus, cerebral cortex, putamen, 
hippocampus, cerebellum, amygdala, thalamus and 
substantia nigra [10]. Today there is substantial evidence that 
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in particular IGF-I is involved in neuroprotection, 
regeneration and brain plasticity [1]. The evidence is 
accumulating that IGF-I has important functions in the 
development and differentiation of the central nervous 
system [11] and in the modulation of growth and 
development of neurons in the dentate gyrus of the 
hippocampus [1]. In a study of van Dam et al. [12], levels of 
N-acetylaspartate (NAA), a marker of neuronal density and 
integrity, and choline, a marker of membrane synthesis were 
measured in adult GH deficient patients. It appeared that 
patients showed decreased N-acetylaspartate (NAA) levels 
and NAA/choline ratios, while plasma IGF-I was 
significantly correlated with brain NAA levels. The 
correlation between IGF-I and brain NAA indicates that 
IGF-I is likely to be involved in the activity of specific 
central nervous pathways, low IGF-I being associated with 
neuronal damage. In elderly subjects low IGF-I levels have 
been found to be associated with a poor outcome after 
ischemic stroke [13].This finding suggests that circulating 
IGF-I may influence the outcome of ischemic stroke. The 
importance of IGF-I for recovery after stroke has indeed 
been suggested by the results of studies in patients during 
rehabilitation after ischemic stroke. Improvement in 
functional and cognitive scores, as well as favorable 
outcome, were associated with higher IGF-I levels, which 
may reflect the neuroprotective role of IGF-I [14,15]. 
 Finally, IGF-I potentiates acetylcholine release from the 
hippocampus [16] while Sonntag et al. [17] reported that 
IGF-I supplementation in rats appears to increase receptor 
subunits 2A and 2B of the hippocampal NMDA receptor. 
 The multiple biochemical and neurophysiological 
mechanisms associated with the GH/IGF-I axis strongly 
support the view that GH and IGF-I have an important 
regulatory role in brain processes. 
COGNITIVE DEFICITS IN GH DEFICIENT 
PATIENTS 
 As is indicated above there is convincing evidence that 
the GH/IGF-I axis may directly be involved in cognitive 
functioning. Indeed, a number of studies have revealed that 
growth hormone deficiency (GHD) is associated with 
cognitive deficits. For instance, patients with GHD suffer 
from lapses of attention, difficulty in concentrating, 
forgetfulness, impaired spatial learning and lower perceptual 
speed [18-21]. Also, GH deficient patients show memory 
impairment, subnormal IQ scores and a low educational level. 
These manifestations are associated with a low IGF-I 
concentration, indicating that subnormal cognitive performance 
is specifically related to GHD [22]. Lijfijt et al. [23] observed 
impairments in selective attention and a decrease in 
attention-related brain potentials in GH deficient patients, 
possibly associated with the functioning of the anterior 
cingulated cortex. In another study, verbal memory as 
measured by the 15-word recall score, and planning 
behavior, processing speed and attention as measured by the 
trail making test were found to be impaired in GH deficient 
adult patients [12]. In the same year, Arwert et al. [24] 
reported a subnormal working memory speed, in particular at 
higher task loads, which were established during functional 
magnetic resonance imaging (fMRI). In contrast to the 
reduced speed, the quality of working memory performance 
appeared to be normal. The imaging data showed that 
patients had increased activity in dorsolateral/ventrolateral 
prefrontal cortex, anterior cingulate cortex, parietal cortex, 
supplementary motor and motor cortex, as well as in the 
thalamus and precuneus area. From these data it is concluded 
that compensatory recruitment of dorsal prefrontal brain 
regions is likely responsible for the normal quality of 
memory performance. Furthermore, from the 
neuropsychological and imaging data they infer that the 
GH/IGF-I axis may be associated with an altered prefrontal 
functioning in GH deficient patients. 
 It is important to be aware that subgroups of GHD 
patients may exhibit a different psychological profile. 
Therefore, cognitive skills should be determined specifically 
for childhood-onset GHD (CO-GHD) and adult-onset GHD 
(AO-GHD). The available data from these subgroups of 
patients suggest that cognitive functions are disturbed to a 
larger extent in patients with CO-GHD than in those with 
AO-GHD. This may indicate that GH and/or IGF-I are 
important for brain development during childhood, and 
possibly also in the prenatal phase [12]. Indeed, in congenital 
GH/IGF-I deficiency a subnormal size of the brain as 
expressed by the below normal head circumference has been 
observed [25]. Furthermore, adolescents and adults with GH 
insensitivity (Laron syndrome), a hereditary disease resulting 
in lack of IGF-I generation appear to suffer from intellectual 
and cognitive deficits [26] and exhibit brain abnormalities as 
revealed by MRI [27]. Finally, the degree of organic brain 
dysfunction and intellectual defects was found to correlate 
with mutations in the GH receptor [28]. 
 A second distinction can be made with respect to the 
extent of the pituitary failure which leads to the diagnosis of 
isolated GHD (IGHD), in which condition only the GH 
secretion is insufficient, or multiple pituitary hormone 
deficiency (MPHD), indicating the presence of GHD in 
addition to an impaired secretion of other pituitary hormones 
(i.e. ACTH, TSH, gonadotropins). The low levels or absence 
of these other pituitary hormones may, even if they are 
replaced, impair brain function more than isolated GH 
deficiency. Indeed, as the distribution of IQ scores for patients 
with isolated growth hormone deficiency (IGHD) has been 
found to be in the upper and for those with multiple pituitary 
hormone deficiency (MPHD) in the lower part of the curve, a 
combined deficiency of pituitary hormones seems more 
harmful for the brain than GHD alone [29,30]. Thus, GHD 
patients do not belong to a homogenous group and cognitive 
deficits of these patients may be related to a subnormal brain 
development as a consequence of GHD in childhood or a 
GH-specific disturbance in neural cell metabolism due to a 
lowered activity of the somatotropic axis. The latter may 
result from traumatic brain injury or brain damage caused by 
a tumor and its concomitant surgical treatment and/or 
irradiation. Finally, inadequate replacement with thyroxin, 
adrenal or sex steroids may adversely affect psychological 
functions. 
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 The last five years no new data on the relationship 
between GH deficiency and cognitive functions have become 
available. The data up until 2005 indicate that irrespective of 
the type of GHD, all patients with GH deficiency are likely 
to suffer from some kind of cognitive impairment. If we look 
at the cognitive deficits in specific subgroups of GHD 
patients, it seems legitimate to conclude that cognitive 
functions are disturbed to a larger extent in patients with CO-
GHD than in those with AO-GHD. This difference may be 
due to the importance of GH and/or IGF-I for brain 
development during childhood and possibly the prenatal 
phase. In addition, there is some evidence that the low levels 
or absence of other pituitary hormones such as ACTH, TSH 
and gonadotropins additional to the deficiency of GH in 
MPHD patients may impair brain function more severely 
than the deficiency of unaccompanied GH in patients with 
isolated GH deficiency. 
COGNITIVE EFFECTS OF GH REPLACEMENT IN 
CO-GH DEFICIENT PATIENTS 
 More than two decades ago the first studies on the effects 
of GH replacement in GH deficient adult patients were 
initiated. One of the first was an uncontrolled study by 
Almqvist et al. [31] reporting an improvement of memory 
functions after 4 weeks of GH replacement in 5 patients with 
CO-GHD. Some years later, the results of a double-blind, 
placebo-controlled crossover study of GH treatment for 12 
weeks in 6 GH deficient patients indicated an absence of any 
beneficial effect of GH replacement on cognition [32]. In 
contrast to this study, results of an uncontrolled study by 
Sartorio et al. [33] showed an improved intellectual 
functioning in 8 CO-GHD patients after 6 months of GH 
therapy. These results were partly confirmed in a study in 48 
CO-GHD men, with a 6-month placebo-controlled design 
followed by an uncontrolled 10-year period of GH treatment. 
There were no GH treatment effects during the placebo-
controlled phase in patients whose serum IGF-I had been 
normalized. However, during the placebo-controlled 
treatment phase patients receiving supraphysiological GH 
treatment, that is IGF-I levels rising to a value exceeding the 
normal upper limit, showed memory improvements. In the 
group with normalised IGF-I levels, memory functioning 
was found to be improved after one year. From these 
findings it was concluded that GH treatment improves 
memory function in adults, while supraphysiological 
treatment accelerates the recovery of memory performance 
[34]. The memory improvements observed after one year of 
GH replacement appeared to be maintained after the 10 year 
follow-up in a remaining group of 23 men, thus implying 
that GH therapy has to be continued for a long period to 
maintain cognitive improvement and to prevent a relapse 
[35]. In line with these findings are the results of a preceding 
study on the effects of one year of GH replacement 
following a 1-year period of GH discontinuation in adult 
CO-GHD patients [36]. No improvements in memory 
function were found within one year of GH treatment, 
providing additional support for the view that a minimum 
treatment period of 1 year is required to improve cognitive 
functions. 
 Although the above cited data on the effects of GH 
replacement in CO-GHD patients up until 2005 are scarce, 
there are no later studies on this issue in the last 5 years. 
Moreover, the evidence of beneficial cognitive effects of GH 
treatment in this subgroup of patients is not overwhelming. 
From the open studies by Alqvist et al. [31], Sartorio et al. 
[33], Arwert et al. [35] and Stouthart et al. [36] three studies 
report a beneficial effect on cognition. However, the results 
of both placebo-controlled studies by Degerblad et al. [32] 
and Deijen et al. [34] indicate an absence of any GH-
treatment effect, except for 6 months of supraphysiological 
treatment. Thus, although limited there is evidence in favour 
of the cognitive enhancing effects of GH replacement in 
adults with CO-GHD which effects may be facilitated by 
administering supraphysiological GH doses. 
COGNITIVE EFFECTS OF GH REPLACEMENT IN 
AO-GH DEFICIENT PATIENTS 
 Also with respect to the cognitive effects of GH 
treatment in AO-GHD, only a handful of studies has been 
performed. Baum et al. [37] reported the results of a 
placebo-controlled study in GH deficient men indicating the 
absence of improved cognitive performance, including 
memory, after 18 months of GH replacement. Soares et al. 
[38] studied attention and memory performance in 9 GHD 
adults (2 with CO-GHD, 7 with AO-GHD) before and after 6 
months of GH treatment in a placebo-controlled trial. After 6 
months of treatment significant improvements were observed 
in diverse cognitive function tests, including memory. Partly 
in line with these findings are the results of an 18-month 
placebo-controlled study reporting improved attention after 
at least 3 months of GH replacement. However, even after 18 
months of GH treatment the improved attention was not 
accompanied by improved memory performance [39]. 
 The most recent controlled study of the cognitive effects 
of GH, which was also the first in elderly patients with 
GHD, was a placebo-controlled, parallel study in patients 
receiving GH or placebo for 52 weeks. The included patients 
were males or females aged 60-80 years. Cognitive function 
was assessed at weeks 0, 24 and 52 using a battery of 
psychometric measures. From the included 34 AO-GHD 
patients (22 males and 12 females) with a mean age of 66 
years 16 received GH treatment and 18 placebo treatment. 
After 6 months the GH treated group exhibited a small 
improvement in memory performance as measured by the 
digit learning test. At the 12 month assessment, significant 
cognitive benefits of growth hormone were no longer found 
[40]. As the significant difference between GH and control 
group were in part due to a decline in performance in the 
placebo group and no effects were seen after 12 months of 
treatment, this study provides a quite limited evidence of a 
beneficial cognitive effect of GH treatment. 
 From the above-cited four placebo-controlled studies 
three provide evidence that GH improves performance in 
diverse cognitive domains, although effects on memory are 
not consistently found. Thus, with respect to GH 
replacement in AO-GHD patients we may conclude that 
evidence of beneficial cognitive effects is scarce, although 
the controlled character of the supportive studies makes the 
The Involvement Of The GH/IGF-I Axis in Cognitive Functions The Open Endocrinology Journal, 2012, Volume 6    71 
treatment effects more convincing than those in CO-GH 
deficient patients. 
THE GH/IGF-I AXIS AND GH TREATMENT IN 
ADULTS WITH PRADER WILLI SYNDROME 
 It is generally known that Prader Willi syndrome (PWS) 
patients exhibit mental retardation ranging from a moderate 
to quite substantial extent. Some studies report a mean full-
scale intelligence quotient (IQ) between 50 and 70, while 
other studies report scores ranging from 35 to 100 or even a 
normal to borderline full-scale IQ score [41-47]. In addition, 
cognitive deficits in PWS patients has been indicated by 
General Intellectual Ability scores that are substantially 
lower than those of sibling control subjects [48]. PWS 
patients also show brain abnormalities, as structural MRI 
scans showed white matter lesions in PWS subjects in 
cortical, subcortical and periventricular regions. 
Furthermore, decreased brain volume in the parietal-occipital 
lobe, ventriculomegaly, Sylvian fissure abnormalities and 
lack of complete insula closure was described in PWS 
subjects [48]. 
 Muscle mass and lean body mass have been found to be 
decreased in PWS patients, and fat mass increased in obese 
as well as non-obese patients with PWS when compared to 
subjects with simple obesity and a corresponding BMI [49-
54]. The abnormal body composition in PWS is comparable 
to the body composition observed in GH deficient patients 
[49,51,52]. Moreover, in obese and non-obese PWS patients 
low levels of free IGF-I are described in addition to 
decreased GH secretion after pharmacological stimulation 
[55,56]. Thus, children and adults with PWS may exhibit GH 
deficiency which appears to be independent of the obese 
state. 
 It is known that cognitive functions, in particular 
attention and memory, are impaired in adults with GHD [57] 
and serum IGF-I levels in healthy elderly subjects correlate 
positively with cognitive performance [58]. Since part of the 
PWS patients are diagnosed as having GHD and show low 
levels of IGF-I it is worthwhile to know whether a 
relationship between IGF-I and cognitive functioning can 
also be observed in adults with PWS. Evidence of such a 
relationship may call for further studies that examine 
whether GH replacement may improve cognitive function in 
adults with PWS. Recently a relationship between IGF-I 
levels and cognition in adults with PWS was indeed 
established. In this study in15 adult PWS patients (4 males) 
with a median age of 22 years (range 19.2-42.9 years) IGF-I 
levels, IQ as measured by the Raven Coloured Progressive 
Matrices (CPM)) and cognitive function as determined by 
four subtests of the Cambridge Neuropsychological 
Automated Testing Battery(CANTAB) were compared with 
the measurements in 14 healthy siblings (7 males), median 
age 28 years (range 17.5-41.3 years). In addition, within the 
PWS patient group the correlation was calculated between 
serum IGF-I levels and cognitive measures. PWS patients 
were found to have lower IGF-I levels and IQ scores as well 
as an impaired performance on tasks measuring temporal as 
well as prefrontal cognitive functions. Notably, within the 
PWS patient group IGF-I levels appeared to correlate quite 
substantially (r = 0.64) with Raven IQ scores [59]. As higher 
IGF-I levels indeed appear to be related to better intellectual 
skills in PWS patients, it seems reasonable to examine 
whether GH treatment would improve intellectual functions 
in adult PWS patients. In the past years results from only one 
study on the cognitive effects of GH treatment in adults with 
Prader-Willi syndrome have been reported [43]. In this study 
9 females and 10 males with a median age of 25 years were 
treated with GH. Half of the group had GH deficiency. After 
6 months of GH treatment there were significant 
improvements in the TMT B test measuring cognitive 
flexibility and in reaction time. After 18 months of GH 
treatment improvements were seen in the block design test 
measuring perceptual organization. Thus, the results suggest 
that GH treatment may improve mental speed, perceptual 
skills and cognitive flexibility in adult patients with PWS. 
THE GH/IGF-I AXIS AND GH TREATMENT IN TBI 
PATIENTS 
 Traumatic brain injury (TBI) has been found to lead to 
hypothalamo-hypophyseal impairment and subsequent 
abnormalities in hormone secretion [60,61]. The underlying 
pathophysiological cause for pituitary insufficiency (PI) is 
thought to be venous infarction following the distribution of 
the long hypophyseal portal veins [62]. The prevalence of 
pituitary/hypothalamic abnormalities after TBI has been 
found quite high as hypopituitarism is present in 30% to 55% 
of patients and severe growth hormone deficits in 15% to 
20% of adult patients [63-67]. Deficiency of hormones due 
to hypopituitarism appears to reflect a time-dependent 
change of the function of the pituitary. A number of patients 
suffering from hypopituitarism in the acute phase of TBI, 
that is within 3 months after head trauma, recover in the 
chronic phase, although also new incidences of 
hypopituitarism are observed [67-70]. Aimaretti et al. [69] 
reported the occurrence of hypopituitarism after head trauma 
in the acute phase in 33% of the patients. In respectively 
5.7%, 5.7% and 21.4% panhypopituitarism, multiple and 
isolated pituitary hormone deficiencies were observed. While 
panhypopituitarism was still seen after 12 months, the 
multiple and isolated deficiencies only continued in 25 % of 
the patients. After 12 months in 5.5 % of the patients who 
were not deficient in the acute phase an isolated deficiency 
was found. In another study the function of the pituitary 
recovered in 57.7 % of the posttraumatic patients after a year 
while new hormone deficiencies became obvious in 51.9 % 
of the patients [70]. In a recent study the prevalence of 
anterior pituitary dysfunction 12 years (SD = 8 months) after 
TBI was determined in 246 patients (mean age 39 years, SD 
= 14 yrs, 133 males). Some degree of impaired pituitary 
function was observed in 21 % of these patients. Total, 
multiple and isolated deficits were present in 1%, 2% and 
18% respectively. In 5% of the patients GHD was 
confirmed. With respect to IGF-I, 19% had an IGF-I level 
that was lower than 1 SDS and 9% had an IGF-I level lower 
than 2 SDS [71]. 
 Although the persisting cognitive deficits after TBI are 
thought to be caused by a post-contusion or post-traumatic 
syndrome, these impairments could also be (partly) caused 
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by hypopituitarism [66]. To determine whether cognitive 
impairments in TBI patients may be due to hormonal deficits 
or to the brain injury itself neuropsychological assessments 
were performed in 22 TBI patients (11 with isolated GH 
deficiency). The results indicated that TBI patients with 
GHD exhibited larger deficits in attention, executive 
functioning and memory than those without GHD [72]. 
These GH-related cognitive impairments in patients who 
develop GHD after TBI may improve with treatment of the 
GH deficiency. A similar study on the relationship between 
pituitary function and outcome from TBI concerned 72 
patients (56 males; mean age 37.2 years), 10 with moderate 
and 52 with severe TBI. Within this group of patients 10 had 
GHD, while overall pituitary dysfunction occurred in 22 
(30.5%) and anterior hypopituitarism in 19 (26.4%) patients. 
A GH peak after GHRH+ARG testing was found to correlate 
positively with cognitive recovery (Level of Cognitive 
Functioning Scale; LCFS), and a higher degree of cognitive 
disability as measured by the LCFS was observed in patients 
with hypopituitary function as compared with those with 
normal pituitary function. As GH peak appears an 
independent predictor of the improvement in cognitive 
abilities, a favourable outcome from TBI is likely associated 
with a better GH reserve [73]. 
 The above cited studies suggest that, once 
hypopituitarism is diagnosed, GH treatment can improve 
neuropsychological performance of TBI patients. However, 
the last years only few studies have been performed on the 
effects of GH replacement on cognitive functions after TBI. 
One of these is a recent report on the effect of GH treatment 
in one GH deficient subject recovering from mild TBI [74]. 
The subject was a 43-year Caucasian female who had been 
involved in a head-on motor vehicle accident at the age of 37 
years. As a consequence she suffered a mild TBI. The 
subject was diagnosed with adult-onset GHD and was 
administered with rhGH subcutaneously per day for 1 year. 
Neuropsychological tests were administered at baseline and 
after 6 and 12 months of GH treatment. To evaluate change 
at the individual patient level, a Reliable Change Index 
(RCI) methodology was employed. However, with respect to 
the neuropsychological evaluation reliable improvements on 
tests of cognition were not found. The subject only 
demonstrated improvements over time on a test of motor 
dexterity and speed. The authors attribute these findings to 
physical improvements observed during the study. More 
substantial evidence was provided by a study in 83 subjects 
with moderate to severe TBI. Patients, at least one year but 
mostly several years post-injury, were screened for GHD 
[75]. Out of the 43 of the 83 subjects that were found to have 
GHD or GH insufficiency 23 agreed to be randomized and 
treated with rhGH or placebo for one year. Twelve subjects 
received active rhGH and 11 subjects received placebo. The 
mean age of the placebo group was 39.1 (SD 8.5) and that of 
the active rhGH group 36.1 years (SD 10). Before and after 
treatment neuropsychological tests were administered. 
Differential improvements between the treatment and 
placebo groups was observed on four measures, i.e. simple 
motor speed, information processing speed, executive 
functioning and memory. The authors conclude, with the 
restriction that the data need to be interpreted cautiously due 
to small sample size and multiple comparisons, that 
cognitive impairments in persons with moderate to severe 
TBI may actually be the result of GHD and seems partially 
be reversible with GH replacement. Some minor support for 
this finding is provided by the results of a study in two 
retired amateur boxers [76]. The repetitive head trauma 
seemingly had a cumulative effect for the development of 
pituitary dysfunction as in both boxers severe isolated GHD 
was diagnosed. After the administration of rhGH for 6 
months QoL-AGHDA scores were decreased relative to 
baseline, which suggest a beneficial effect of GH treatment 
on quality of life. Unfortunately, no cognitive functions were 
measured. 
 The above cited studies provide substantial evidence that 
TBI may be accompanied by GHD. As TBI patients with 
GHD exhibit larger cognitive deficits than those without 
GHD, it can be assumed that the occurrence of GHD may 
contribute to the harmful consequences of TBI on cognitive 
functioning. Moreover, the finding that even 12 years after 
TBI some degree of impaired pituitary function was 
observed in 21 % and GHD in 5% of the patients suggests 
that GH treatment in TBI patients may be beneficial, also in 
when a long period has elapsed after the traumatic injury. 
Unfortunately, only one study provides some evidence of 
positive effects of GH treatment on cognitive functions in 
TBI patients. More studies are needed to elucidate the 
magnitude of cognitive deficits in moderate to severe TBI 
that are the result of GHD and to examine whether these 
deficits are reversible with GH replacement. 
GH/IGF-I AXIS AND COGNITIVE AGING IN 
HEALTHY ADULTS 
 Normal aging is accompanied with a reduced activity of 
the GH/ IGF-I axis. In addition, both GH deficiency and 
aging are characterized by the occurrence of impaired 
cognitive functions. After the age of 40 the amount of GH in 
humans progressively decreases and an increasing age-
associated cognitive impairment is seen [19]. As IGF-I levels 
have been found associated with cognitive functioning, the 
reduced circulating IGF-I levels may play a role in age-
related cognitive decline. Indeed, IGF-I plasma levels of 
healthy elderly have been found positively associated with 
Mini Mental State Examination (MMSE) scores [77]. 
Similarly, IGF-I levels in elderly healthy men were found to be 
associated with better performance in tests sensitive to the 
effects of aging, especially speed of information processing 
[78] and verbal fluency and MMSE [79]. With respect to age-
related cognitive impairments, higher serum total IGF-I levels 
in healthy subjects above 55 years were associated with less 
cognitive decline over the following two years. In this study 
the Mini-Mental State Examination (MMSE) was used to 
assess cognitive impairment at baseline and cognitive 
decline after, on the average, 1.9 year of follow-up [80]. In 
two studies separately performed in males and females, 
cognitive functions of subjects of 65 years and older were 
related to levels of free IGF-I and IGF-I to IGFBP-3 molar 
ratio determined from stored blood samples. Cognitive 
functions were assessed by means of telephone-based tests. 
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Levels of free IGF-I measured in blood samples collected at 
a mean age of 57 years in the men were positively related to 
global and verbal memory performance on average of 18 
years later, and IGF-I levels collected at a mean age of 56 
years in women to general cognition on average of 10 years 
later. These results indicate that higher midlife free IGF-I 
may be associated with better late-life cognition [81,82]. 
Quite recently, low IGF-I levels were found to be associated 
with cognitive decline in hypertensive elderly subjects aged 
65 year and older [83] and with a prolonged latency of the 
P300 event-related potential, which may predict cognitive 
decline, in males aged between 30 and 50 years [84]. The 
relationship between the GH/IGF-I axis and working 
memory performance was studied in 24 elderly males and 
females, aged 75-85 years. These subjects were selected 
from a sample of 1318 elderly subjects based on belonging 
to highest or lowest IGF-I quartiles. Positron emission 
tomography (PET) was used to measure regional blood flow 
during the performance of a delayed-non-matching to sample 
(DNMTS) working memory task. It appeared that the high 
IGF-I group had a higher working memory speed and a 
larger increase in cerebral blood flow in the left premotor 
and left dorsolateral prefrontal cortex. This has lead the 
authors to conclude that healthy elderly with high IGF-I 
levels exhibit a faster working memory performance and an 
increased recruitment of task-associated prefrontal regions 
[85]. Another large (n = 353) study in still older subjects 
determined the relationship of total serum free IGF-I and its 
binding protein-3 with cognitive performance in persons 
aged 80 years and older. After adjustment for potential 
confounders, individuals with verbal expression and/or 
comprehension problems had significantly lower IGF-I 
levels than subjects without cognitive impairments. Also this 
study supports the notion that the GH/IGF-I axis may play an 
important role in the age-related decline of cognitive 
performance [86]. In another group of subjects aged 65 to 92 
years presenting no malnutrition and no inflammation 
plasma concentrations of IGF-I, IGF-II and IGFBP3 were 
found to be reduced as compared to a healthy reference 
group of subjects aged 20 to 65 years [87]. 
 Quite recently the relationship between IGF-I, cognitive 
functioning and neuroimaging was investigated in a sample 
of 75 hypertensive elderly subjects aged 65 years and over. 
Cognitive performance was tested by the mini mental state 
examination (MMSE), Cambridge cognitive examination 
(CAMDEX-R), and the frontal assessment battery (FAB). 
Among other indices, free IGF-I in serum was assayed and 
the radial width of the temporal horn (rWTH) was 
determined to evaluate medial cerebral temporal lobe 
atrophy. Significant correlations between IGF-I levels and 
total as well as sub-domain scores of cognition were found. 
The lowest IGF-I percentile subgroup was significantly 
cognitively impaired. Levels of IGF-1 below 79.4 microg/l 
were associated with cognitive decline, whereas a level 
above 118 microg/l seemed to be a marker of normal 
cognitive performance. A statistically non-significant, but 
lower IGF-I level was found in the subsample with 
pathologically wider rWTH. This widening of the rWTH  
 
related with a decreasing IGF-I level suggests an 
involvement of IGF-I in hippocampus atrophy [83]. Finally, 
a most recent study in healthy males (mean age 61.2 years, 
range 50-78) reported that measures of selective attention, 
short-term memory and processing speed were positively 
associated with GH secretion [88]. 
 The results of the above cited studies clearly support the 
notion that the GH/IGF-I axis may play an important role in 
age-related cognitive decline in healthy subjects. More 
specifically, there is some evidence that reduced levels of 
IGF-I are involved in hippocampus atrophy. Based on these 
findings some studies examined the effects of stimulating the 
activity of the GH/IGF-I axis on cognitive performance in 
healthy subjects. The first study investigated the stimulatory 
effect of an orally administered nutritional supplement, 
containing glycine, glutamine and niacin on the GH-IGF-I 
axis and cognition in healthy middle-aged and elderly 
subjects. Fourty-two healthy subjects (14 men and 28 
women, aged 40-76 years) were enrolled in a randomized, 
double blind, placebo-controlled trial. They received 5 g of a 
nutritional supplement or placebo, twice daily orally for a 
period of 3 weeks. At baseline and after 3 weeks, blood was 
collected for measurement of serum GH and IGF-I levels 
and cognitive function were tested. The ingestion of the 
nutritional supplement for 3 weeks was found to increase 
serum GH levels with 70% relative to placebo, whereas 
circulating IGF-I levels did not change. Mean GH increased 
in this group from 3.23 to 4.67 mU/l. Although GH increase 
did not improve average cognitive performance, correlation 
analyses revealed that individual increases in IGF-I, but not 
GH, were associated with improved memory [89]. A second 
study investigated whether age-related cognitive decline may 
be arrested or partially reversed by hormonal supplementat-
ion. The effect of 6 months treatment with daily growth 
hormone releasing hormone (GHRH) or placebo on the 
cognition of a group of 89 healthy adults with a mean age of 
68 years (SD = 0.7) was examined. GHRH resulted in 
improved performance on WAIS-R performance IQ, WAIS-
R picture arrangement, finding A's, verbal sets and single-
dual task. GHRH-based improvements were independent of 
gender, estrogen status or baseline cognitive capacity [90]. 
 These results demonstrate that age-related cognitive 
impairment may be related to the age-related decline in the 
somatotrophic axis. They further suggest that supplementat-
ion of the somatotrophic axis may reduce cognitive decline 
in healthy older adults. Healthy elderly may increase the 
activity of the GH/IGF-I axis by diet and exercise, because 
these factors can affect mitochondrial energy production. 
Adenosine triphosphate (ATP) produced by mitochondria 
might activate IGF-I, which may support synaptic plasticity 
and cognitive function. Specifically, docosahexaenoic acid 
(DHA), an omega-3 fatty acid that humans mostly attain 
from dietary fish, can activate energy-generating metabolic 
pathways that subsequently affect molecules such as GF-I. 
As IGF-I can be produced in the liver and in skeletal muscle, 
as well as in the brain it can convey peripheral messages to 
the brain in the context of diet and exercise [91]. 
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GH/IGF-I AXIS AND DEMENTIA 
 As IGF-I levels fall with aging and correlate with 
cognitive decline, the possible role of IGF-I levels in the 
development of dementia has been examined. For instance, 
levels of IGF-I and IGF binding proteins (IGFBP’S) were 
studied in patients with Alzheimer’s disease (AD). Patients 
with AD had lowered IGF-I and IGFBP-3 levels and higher 
IGFBP-1 levels relative to controls. IGF-I levels inversely 
correlated with cognitive impairment [92]. In line with this 
study, recently a severe reduction of IGF-I (3.7+1.2 pg/ml 
after GH) was demonstrated in mild to moderate AD patients 
compared to age-matched healthy elderly subjects (IGF-I, 
9.5+/-2.8 pg/ml after GH) [93]. In a similar study in 49 
healthy centenarians (mean age 100.4 year) cognitive 
functioning was assessed by clinical dementia ratings. 
Centenarians with lower IGF-I levels had higher prevalence 
of dementia [94]. 
 There is evidence that brain amyloid clearance is 
modulated by serum IGF-I, which levels in serum appear to 
be altered in Alzheimer's patients. Thus, it has been proposed 
that amyloid clearance by IGF-I can be a potential 
therapeutic target in Alzheimer's disease [95]. Moreover, 
when an acetylcholinesterase inhibitor, such as rivastigmine, 
a drug for AD, is acutely administered, the area under the 
curve of the GH response to GHRH doubles, showing that 
rivastigmine is powerful in the enhancement of GH release. 
Consequently, an emerging clinical target for improving the 
clinical manifestations of AD may be the activation of 
GH/IGF-I, which rejuvenates the axis, so resulting in an 
overall physiological benefit [96]. 
 Currently there is only one report on the effects of 
increase in the activity of the somatotrophic axis on 
symptoms, including cognitive impairment, in patients with 
AD. In this double-blind, multicenter study it was examined 
whether the growth hormone secretagogue MK-677 
(ibutamoren mesylate), a potent inducer of IGF-I secretion, 
reduces the rate of progression of symptoms in patients with 
AD. Patients with mild to moderate AD (n = 563) were 
randomized to receive MK-677 25 mg or placebo daily for 
12 months. Efficacy measures were the Clinician's Interview 
Based Impression of Change with caregiver input (CIBIC-
plus), the cognitive subscale of the Alzheimer's Disease 
Assessment Scale (ADAS-Cog), Alzheimer's Disease 
Cooperative Study-Activities of Daily Living (ADCS-ADL), 
and the Clinical Dementia Rating-sum of boxes (CDR-sob). 
A total of 416 patients completed treatment and assessments 
at 12 months. Administration of MK-677 25 mg resulted in a 
60.1% increase in serum IGF-I levels at 6 weeks and a 
72.9% increase at 12 months. However, there were no 
significant differences between the treatment groups on any 
of the measures over the 12 months. Despite the increase in 
serum IGF-I, the human growth hormone secretagogue MK-
677 25 mg was ineffective at slowing the rate of progression 
of Alzheimer disease [97]. The absence of any effects may 
be due to the possibility that once the Alzheimer pathology is 
established induction of IGF-I may serve little purpose. 
Perhaps this kind of treatment needs to be tested in an early 
stage of the disease. 
GH/IGF-I AXIS AND SCHIZOPHRENIA 
 It has been hypothesised that low levels of IGF-I may 
underlie markers of pre- and post-natal growth and 
development of schizophrenia. Low IGF-I levels are 
associated with low birth weight [98], reduced birth length, 
low body mass index, and at age 18 short height [99]. 
Additionally, evidence suggests that subnormal growth 
during development is associated with an increased risk of 
adult schizophrenia. Impaired fetal growth, famine exposure 
in utero, birth complications, maternal infection and 
childhood meningitis are associated with increased risk 
[100]. Such associations suggest that factors responsible for 
abnormal growth might influence the pathogenesis of 
schizophrenia [101] and because the markers of pre- and 
post-natal growth and development are also associated with 
an increased risk of schizophrenia, they imply a role for IGF-
I in its aetiology [102]. With the actions of GH and IGF-I as 
promoters of growth in childhood [103], a disrupted GH-IGF 
axis may be one of the factors that underlie some of these 
associations [104]. 
 In addition, schizophrenia is associated with an increased 
risk to develop impaired glucose tolerance, insulin 
resistance, and type II diabetes mellitus [105]. In line with 
this, an increased impaired glucose tolerance, higher levels 
of plasma cortisol, insulin and glucose, and a higher insulin 
resistance were shown in first-episode antipsychotic naïve 
schizophrenia patients [106]. Normally, GH promotes a rise 
in blood glucose level, a relative insulin resistance, and a 
reduction in deleterious plasma lipids, whereas IGF-I 
promotes a reduction in blood glucose levels and increased 
insulin tolerance [107]. However, a deficient IGF-I level can 
cause insulin resistance [108]. In order to test the hypothesis 
that schizophrenia patients would have significantly higher 
insulin resistance and lower IGF-I levels than healthy control 
subjects, Venkatasubramanian et al. [109] examined the 
plasma levels of glucose, insulin, IGF-I and cortisol in 
antipsychotic-naïve schizophrenia patients relative to healthy 
control subjects. Schizophrenia patients exhibited a 
significantly higher mean plasma insulin level, as well as 
significantly more insulin resistance. The mean plasma IGF-I 
level was significantly lower in patients and had a negative 
correlation with plasma insulin levels. These results support 
the IGF-I deficiency hypothesis as an interpretation of the 
aetiology of schizophrenia. It is suggested that low IGF-I 
levels might render the brain more vulnerable to 
neurodevelopmental insults potentially culminating in 
schizophrenia. Since IGF-I receptors are concentrated in the 
hippocampus, this brain region is likely to be more affected 
due to IGF-I deficits and alterations in this brain structure are 
associated with psychological disorders including 
schizophrenia. As a conclusion, Venkatasubramanian et al. 
[109] suggest that low levels of IGF-I might be potentially 
involved in the pathogenesis of schizophrenia. 
 With regard to the treatment of schizophrenia with 
antipsychotics, a longitudinal study examined the effect of 
antipsychotic treatment on IGF-I and cortisol in 
schizophrenia [110]. A reciprocal relation was found 
between IGF-I and cortisol. Following antipsychotic 
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treatment, cortisol levels decreased and IGF-I levels 
increased significantly in patients. The larger the reduction 
in cortisol level, the larger was the increase in IGF-I level. 
Furthermore, the larger the increase in level of IGF-I the 
larger was the improvement in positive symptoms. This 
longitudinal study point to the possibility that 
hypercortisolemia can result in decreased IGF-I levels. The 
inverse relationship between cortisol and IGF-I is already 
present in normal newborn infants [111]. It may be 
hypothesised that some effects of hypercortisolemia on the 
pathogenesis of schizophrenia might be mediated trough its 
inhibitory effects on IGF-I secretion. It is possible that 
decreasing the cortisol levels by antipsychotics, might result 
in significant elevation of IGF-I in schizophrenia patients. In 
accordance with the findings of Venkatasubramanian et al. 
[110], the interaction between cortisol and IGF-I supports a 
possible link between HPA axis abnormalities and IGF-I 
deficits in the pathogenesis as well as treatment of 
schizophrenia. 
GH/IGF-I AXIS IN ADULT SURVIVORS OF 
CHILDHOOD LEUKEMIA 
 The prognosis of children with acute lymphoblastic 
leukemia (ALL) has improved dramatically and long-term 
survival rates up to 80% have been reported. Along with this 
development studies have been directed at identifying the 
neuropsychological effects of treatment for ALL in 
childhood. Prophylactic intrathecal (IT) chemotherapy has 
replaced CNS radiation therapy (CRT), as research revealed 
cognitive deterioration and deficits associated with such 
CRT [112]. However, negative effects of high-dose IT 
chemotherapy regimens may occur as it was reported that 
from 43 reviewed studies on the long-term consequences of 
CNS chemotherapy in ALL survivors approximately two 
thirds document a decline in cognitive abilities [113]. From a 
study by Copeland et al. [114] the cognitive side effects of 
IT chemotherapy appeared to be slightly more apparent 5 to 
11 years after diagnosis than at 3-year follow-up. It may thus 
be assumed that cognitive impairment may be present in 
adult survivors of ALL who have formerly been treated with 
CRT or IT chemotherapy. In addition to cognitive deficits 
GHD or impaired GH secretion are frequently found late 
effects in patients treated with CRT and/or chemotherapy for 
childhood ALL. With respect to CRT, the prevalence of 
GHD was established in 75 randomly selected adult 
survivors of childhood ALL treated with or without cranial 
irradiation. The mean age of the subjects was 30 years and 
the mean time since ALL diagnosis was 25 years. It 
appeared that abnormally low GH was present in 85% of 
those who received past cranial irradiation. Thus, cranial 
irradiation was strongly related to GH deficiency and lower 
IGF-I levels [115]. With respect to chemotherapy, 31 
patients who received chemotherapy but no CRT were 
selected from the medical records of 362 childhood cancer 
patients. Out of these patients, 17 had ALL and 1 had acute 
myeloid leukemia. At the initial diagnosis the median age of 
these 18 patients with hematological malignancies was 3.2 
years, and the median age at last follow up was 17.5 years. 
From these patients 9 (50%) developed GH deficiency [116]. 
These findings indicate that GHD may occur in survivors of 
non-CNS tumors who receive chemotherapy without having 
been treated with CRT. 
 As GHD has been found to be associated with cognitive 
deficits and GH treatment may reverse these deficits, GH 
treatment may have positive effects on cognitive functioning 
in adult survivors of pediatric ALL. Based on this 
assumption some studies evaluated the cognitive effects of 
GH treatment in ALL survivors. In the first study 44 adult 
patients (23 males, 21 females) with a median age of 
24?8 years (range 19?8-31?3) were included. They had been 
diagnosed with ALL at a median age of 4 years (1-17). The 
patients had been treated with CRT at a median of 20 years 
(8-27) previously and had been off chemotherapy for a 
median of 16?7 years (6?3-23?9). Compared to controls, the 
former ALL patients had a generally lower performance in 
neuropsychological tests, reaching statistical significance in 
14 of the 20 test variables. In addition, after GH testing all 
patients were considered GH deficient or insufficient. 
Fourteen patients with severe GHD and 14 control subjects 
participated in a follow-up, comprising a repeat 
neuropsychological examination. The former ALL patients 
were treated during 1 year with biosynthetic human GH with 
median final GH dose of 0?4 mg/day (range 0?2-0?6). 
However, treatment with GH for 1 year in this subgroup of 
patients with GHD did not improve their neuropsychological 
performance [117]. 
 A second study on the effects of GH treatment and 
neuropsychological functioning was performed in 20 adult 
survivors of childhood ALL with reduced bone mineral 
density and/or low IGF-I SD-scores (<-1 SD). A final group 
of 13 patients (9 males and 4 females), mean age 23.7 ± 2.9 
years (range 20 - 29.7) completed a 2-year treatment with 
GH. Most subjects (10 of 13) had been treated with regimens 
including prophylactic cranial irradiation. The mean time 
since diagnosis was approximately 15 years. The starting 
dose of GH was calculated as 0.1 mg per square meters of 
body surface. Every two weeks, the dose was increased with 
0.1 mg/m2, until IGF-I rised above 0 SD. 
Neuropsychological performance and IQ were assessed at 
pre-treatment and after one and two years. Since most 
participants received prophylactic cranial irradiation as part 
of their ALL-treatments, it was remarkable that the 
neuropsychological test scores of the subjects appeared to be 
in the normal range, while the level of intellectual 
functioning as determined by IQ tests was even high 
average. Positive treatment effects were found with respect 
to visual-spatial memory and attention, which functions 
improved after one year of treatment. Correlation analysis 
indicated that improvement of visual-spatial memory was 
related to the IGF-I increase in the first treatment year. In 
addition, verbal memory functions were found to be 
negatively affected by GH treatment. As results of the study 
suggest that relationships between GH therapy and 
neuropsychological functioning seem strongly dependent on 
IGF-I levels and an excessive increase of IGF-I seems 
adversely affect verbal memory performance, the authors 
presume that a lower dose of GH may be more effective to 
enhance cognitive functions in ALL survivors [118]. 
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CONCLUSION 
 Current knowledge provides abundant evidence that the 
GH/IGF-I axis is an important regulator of brain function. 
The evidence is based on the knowledge that: 1) GH and 
IGF-I can cross the blood brain barrier, respectively by 
simple diffusion or by a saturable high capacity transport 
system, 2) for GH as well as IGF-I there are binding sites in 
various brain structures, including structures that are 
involved in cognitive functions, like the hippocampus, 3) 
within the hippocampus the DA turnover is altered by GH 
and the acetylcholine release by IGF-I, and 4) GH and IGF-I 
likely contribute to long-term potentiation of synaptic 
efficacy in the hippocampus by activating the NMDA 
receptor. On a behavioural level, there is evidence that the 
biochemical and neurophysiological mechanisms associated 
with the activity of the GH/IGF-I axis may directly affect 
cognitive functioning. Indeed, the reduced activity of the 
GH/IGF-I axis appears to be related with impaired cognitive 
function in a diversity of groups of subjects with intellectual 
disabilities such as patients with GHD, Prader-Willi 
syndrome, TBI, dementia but also in healthy adults. 
Moreover, IGF-I deficiency may be involved in the aetiology 
of schizophrenia. As a consequence, the effects of GH 
treatment on cognitive functions have been examined in 
patient groups and healthy elderly subjects. Although the 
results of studies are contradictory, the general finding in 
patients with GHD, Prader-Willi and TBI are in favour of a 
beneficial effect of GH replacement in case of pituitary 
dysfunction. From a number of 14 studies on the effects of 
GH replacement in a diversity of patient groups 10 reported 
positive effects of GH replacement on cognition. The 
available data suggest that a treatment period of 
approximately one year is required to improve cognitive 
functions and that GH therapy has to be continued to 
maintain cognitive improvement and to prevent a relapse. 
 In spite of the quite large body of literature on the 
cognitive effects of GH deficiency the number of studies on 
the cognitive effects of GH replacement in distinct groups of 
patients with GHD is still quite limited. Moreover, diet, 
exercise, acetylcholinesterase inhibitors which are prescribed 
in Alzheimer’s disease and antipsychotic treatments have 
known effects on the GH/IGF-I axis. Studies on the 
relationship between diet-, exercise-, or medication-induced 
GH/IGF-I increase and cognition may be useful to explain 
how these interventions affect brain functions. 
 The current knowledge indicates that disturbances of the 
activity of the GH/IGF-I axis may impede optimal brain 
development and function and even be involved in the 
development of schizophrenia and dementia. Moreover, it 
seems justified to assume that GH replacement may directly, 
and diet, exercise as well as anti-dementia or antipsychotic 
medication may indirectly affect the activity of the GH/IGF-I 
axis. The use of GH and IGF-I as therapeutic tools for CNS 
related impairment in conditions with altered GH/IGF-I may 
be expected to increase in the future. It may well be true that 
supplementation with GH or IGF-I can be used to reduce the 
risk of the development of schizophrenia and dementia and 
to attenuate the cognitive sequelae of TBI and ischemic 
stroke. 
 Yet, it seems that the number of studies in this field is 
progressively decreasing which may reflect a reduced 
scientific interest in the role of the GH/IGF-I axis in 
maintaining optimal brain function and intellectual 
performance. To expand the current knowledge more 
scientific research on the involvement of GH deficiency in 
the development of cognitive disorders and the potential of 
GH therapy to slow down cognitive deterioration in diverse 
patient groups with GHD is highly required. 
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